马丽英

一、个人简介

马丽英1998年毕业于华西医科大学，获博士学位，现为中国疫病预防控制中心性病艾滋病预防控制中心病研究员，博士研究生导师，传染病预防控制国家重点实验室艾滋病组PI，性病艾滋病预防控制中心病原生物学课题组负责人，卫生部生物安全和BSL-3评审专家，科技部项目评审专家，国家自然科学基金同行评议人。北京市检验学会委员。2001-2005年在法国和美国留学，近年来在国内外杂志累计发表文章80余篇，其中SCI文章41篇。在<JMC>、<AIDS>、<JAC>、<RETORVIROLOGY>、等国际期刊发表。获2013年中华预防医学科技进步二等奖和北京市科技进步三等奖。申请新药专利四项，授权两项。

二、主要研究方向

1. HIV生物学和致病机制研究；2. HIV的耐药机制和新药物研究

三、代表性科研项目

先后主持承担国家科技部973子课题项目、两项国家自然科学基金课题以及NIH-NSF中美合作项目两项，作为副组长和主要完成人承担科技部863项目，欧盟基础建设第七框架和传染病重大专项以及美国NIH资助的CIPRA和HPTN058等多项国内外重大项目。

1. 代表性论文、成果（2011年以来）
2. Yin, Q. Q. et al. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase. Biomedical and environmental sciences : BES 29, 239-247, doi:10.3967/bes2016.031 (2016)
3. Wang, Y. *et al.* Identification of a Novel CRF01\_AE/CRF07\_BC Recombinant Form in Men Who Have Sex with Men in Sichuan, China. *AIDS research and human retroviruses* **32**, 718-721, doi:10.1089/AID.2015.0276 (2016).
4. Jiao, Y. *et al.* Hepatitis C Virus Subtype and Evolution Characteristic Among Drug Users, Men Who Have Sex With Men, and the General Population in Beijing, China. *Medicine* **95**, e2688, doi:10.1097/MD.0000000000002688 (2016).
5. Cheng, S. *et al.* Enfuvirtide-PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties. *European journal of medicinal chemistry* **121**, 232-237, doi:10.1016/j.ejmech.2016.05.027 (2016).
6. Xu, W. *et al.* The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes. *Antimicrobial agents and chemotherapy* **59**, 4882-4888, doi:10.1128/AAC.00440-15 (2015).
7. Yin, Q. Q., Shao, Y. M. & Ma, L. Y. HIV cure and HIV reservoirs. *Biomedical and environmental sciences : BES* **27**, 478-480, doi:10.3967/bes2014.078 (2014).
8. Li, Z. *et al.* CorMut: an R/Bioconductor package for computing correlated mutations based on selection pressure. *Bioinformatics* **30**, 2073-2075, doi:10.1093/bioinformatics/btu154 (2014).
9. Jiao, Y. *et al.* HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naive MSM from 2011 to 2013 in Beijing, China. *BMC infectious diseases* **14**, 689, doi:10.1186/s12879-014-0689-7 (2014).
10. Huang, Y. *et al.* Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF\_BC strains. *PloS one* **9**, e93804, doi:10.1371/journal.pone.0093804 (2014).
11. OuYang, Y. *et al.* Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China. *Virology journal* **10**, 10, doi:10.1186/1743-422X-10-10 (2013).
12. Li, Z. *et al.* Mutation covariation of HIV-1 CRF07\_BC reverse transcriptase during antiretroviral therapy. *The Journal of antimicrobial chemotherapy* **68**, 2521-2524, doi:10.1093/jac/dkt228 (2013).
13. Li, A. *et al.* Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains. *Journal of medicinal chemistry* **56**, 3593-3608, doi:10.1021/jm400102x (2013).
14. Wang, X. *et al.* Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. *Journal of medicinal chemistry* **55**, 2242-2250, doi:10.1021/jm201506e (2012).
15. Ouyang, Y., Shao, Y. & Ma, L. HIV-1 CRF\_BC recombinants infection in China: molecular epidemic and characterizations. *Current HIV research* **10**, 151-161 (2012).
16. Yu, X. *et al.* Susceptibility of HIV-1 subtypes B', CRF07\_BC and CRF01\_AE that are predominantly circulating in China to HIV-1 entry inhibitors. *PloS one* **6**, e17605, doi:10.1371/journal.pone.0017605 (2011).
17. Huang, Y. *et al.* Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors. *Virology journal* **8**, 230, doi:10.1186/1743-422X-8-230 (2011).
18. Zhang, L. et al. Alterations in HIV-1 gp120 V3 region are necessary but not sufficient for coreceptor switching in CRF07\_BC in China. PloS one 9, e93426, doi:10.1371/journal.pone.0093426 (2014).
19. Wang, Y. et al. Near Full-Length Genome Identification of a Novel HIV-1 Unique (B/C) Recombinant Isolate in Sichuan, China. AIDS research and human retroviruses, doi:10.1089/AID.2016.0087 (2016).